RT Journal Article
SR Electronic
A1 Alexander, Lori
T1 HPS2-THRIVE Results
JF MD Conference Express
YR 2012
FD SAGE Publications
VO 12
IS 13
SP 27
OP 28
DO 10.1177/155989771213019
UL http://mdc.sagepub.com/content/12/13/27.abstract
AB Approximately two thirds of patients can tolerate extended-release niacin when combined with laropiprant, according to a prespecified interim safety and tolerability analysis of the Heart Protection Study 2: Treatment of HDL to Reduce the Incidence of Vascular Events [HPS2-THRIVE; NCT00461630] study. The addition of niacin/laropiprant to statin therapy offers a dual goal of decreasing low-density lipoprotein-cholesterol and increasing high-density lipoprotein-cholesterol.